Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.

Publication Type:

Journal Article


Cancer, Volume 119, Issue 20, p.3703-9 (2013)


Antineoplastic Agents, Hormonal, Breast Neoplasms, Cross-Sectional Studies, Cytochrome P-450 CYP2D6, Female, Follow-Up Studies, Humans, Medical Oncology, Middle Aged, Pharmacogenetics, Physician's Practice Patterns, Polymorphism, Genetic, Prognosis, Tamoxifen


This study evaluated self-reported knowledge, practice, and attitudes toward commercially available cytochrome P450 2D6 (CYP2D6) pharmacogenomic testing for patients on tamoxifen for breast cancer (CYPT) among US oncologists while evidence for the use of the test was evolving.